Howard L. Foyt
Chief Tech/Sci/R&D Officer at ViaCyte, Inc.
Profile
Howard L.
Foyt is currently the Chief Medical Officer at ViaCyte, Inc. He previously held positions as the Medical Director-Diabetes Center at the University of Texas Medical Branch from 1991 to 1996, Senior Director-Medical & Development Sciences at Pfizer (St. Louis) from 2000 to 2005, Director-Clinical Research, Endocrine & Metabolism at Parke-Davis Pharmaceutical Research, Inc. from 1996 to 2000, and Vice President-Clinical Development at Metabasis Therapeutics, Inc. from 2006 to 2008.
He has also served as the Chief Medical Officer & Senior Vice President at Cebix, Inc. and as the Chief Medical Officer & Executive VP-Development at Ritter Pharmaceuticals, Inc. Dr. Foyt obtained his doctorate degree from Baylor College of Medicine in 1985.
Howard L. Foyt active positions
Companies | Position | Start |
---|---|---|
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
Former positions of Howard L. Foyt
Companies | Position | End |
---|---|---|
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | Corporate Officer/Principal | 2008-11-11 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Chief Tech/Sci/R&D Officer | 2004-12-31 |
Parke-Davis Pharmaceutical Research, Inc. | Chief Tech/Sci/R&D Officer | 1999-12-31 |
University of Texas Medical Branch | Corporate Officer/Principal | 1995-12-31 |
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
Training of Howard L. Foyt
Baylor College of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 6 |
---|---|
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | Health Technology |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Health Technology |
Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA. | Health Technology |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Health Technology |
Parke-Davis Pharmaceutical Research, Inc. |
- Stock Market
- Insiders
- Howard L. Foyt